ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

A nationwide study of older adults in Sweden suggests a suspected link between antibiotic use and microscopic colitis is more ...

The intestinal epithelium is a highly dynamic barrier that regulates digestion, absorption, immune responses, and ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...